GlaxoSmithKline's sales fell 10%, highlighting the pressures behind last week's decision to trade more than $20 billion of assets with Novartis.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Brent Saunders, CEO of Forest Labs, discusses his company's acquisition by Ireland-based Actavis.
Rhenu Bhuller, Senior VP of Healthcare at Frost & Sullivan, says the rush of deals in the pharmaceutical sector may be a manifestation of the struggles that industry players are facing.
Sachin Shah, Analyst at Albert Fried & Company, says declining sales is one of the factors fueling the flurry of deals in the pharmaceutical sector.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Alex Tarrant, M&A reporter at Dealreporter, discusses the implications of a potential deal between Pfizer and AstraZeneca.
CNBC's David Faber reports on Bill Ackman and Valeant's bid for Botox maker Allergan, and a look at how tax inversions are fueling pharma deals.
It's "too early to tell" if President Barack Obama's signature health care law is successful, Aetna CEO Mark Bertolini told CNBC.
CNBC's Meg Tirrell reports a Cowen analyst is suggesting Allergan buy ADHD drug maker Shire. The FMHR traders, provide perspective.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.
James West, healthcare analyst at Results Healthcare, says the pharmaceutical sector is "dynamic" and the flurry of deals is likely to continue.
CNBC's Eamon Javers reports on Bill Ackman's stake in Allergan. Javers says this is a classic case of insider trading that is not against the rules.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.